Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
EPA CPDat observed this chemical in 2644 composition records across product categories including Construction and building materials, Furniture and furnishings, Raw materials.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 · limited confidence.
Prevalence of ACETIC ACID in our catalog (epa_cpdat).
Products
2,644
Brands
6
Typical roles
Catalog
Co-occurrence
Ingredients that frequently appear alongside ACETIC ACID in the catalog.
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
Fragrance avoidance
Not a strong fit for fragrance avoidance because it carries Fragrance.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
EPA
EPA CPDat observed this chemical in 2644 composition records across product categories including Construction and building materials, Furniture and furnishings, Raw materials. EPA CPDat classifies this chemical for functional uses including pH regulating agent, Deodorizer, Fragrance.
US
FDA
Route: AURICULAR (OTIC); Dosage form: SUSPENSION; Potency: 0.26 %w/v
US
FDA
Pain de mie grandes tranches Toastiligne complet
la boulangère
The ingredient itself is a fragrance-linked signal, so it is better treated as an avoid case when fragrance exposure is the main concern.
The published evidence profile currently shaping this ingredient record.
Route: AURICULAR (OTIC); Dosage form: SUSPENSION/ DROPS; Potency: 0.04 %w/v
US
FDA
Route: ENDOTRACHEAL; Dosage form: SUSPENSION; Potency: ADJ PH
US
FDA
Route: INFILTRATION; Dosage form: INJECTION; Potency: NA
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 22 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, EMULSION; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRASYNOVIAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Maximum daily exposure: 827 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, EMULSION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Maximum daily exposure: 3 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 15 mg
US
FDA
Route: INTRAVENOUS; Dosage form: LIQUID; Potency: 0.2 %w/v
US
FDA
Route: INTRAVENOUS; Dosage form: SOLUTION; Maximum daily exposure: 14 mg
US
FDA
Route: IRRIGATION; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: NASAL; Dosage form: SPRAY, METERED; Potency: 1.2 mg/1ml
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION; Maximum daily exposure: 3 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION/ DROPS; Potency: 0.09 %w/v
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED; Maximum daily exposure: 1 mg
US
FDA
Route: ORAL; Dosage form: ELIXIR; Potency: 1.07 mg/5ml
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 10 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 12 mg
US
FDA
Route: ORAL; Dosage form: SYRUP; Maximum daily exposure: 10 mg
US
FDA
Route: PARENTERAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: SOFT TISSUE; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION; Maximum daily exposure: 22 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, EMULSION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: ADJ PH
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Maximum daily exposure: 32 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 4 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: LIQUID; Potency: 0.2 %w/v
US
FDA
Route: SUBCUTANEOUS; Dosage form: SOLUTION; Potency: 0.06 %w/v
US
FDA
Route: SUBMUCOSAL; Dosage form: INJECTION, SOLUTION; Potency: ADJ PH
US
FDA
Route: TOPICAL; Dosage form: SOLUTION; Potency: ADJ PH
US
FDA
Route: VAGINAL; Dosage form: AEROSOL, FOAM; Potency: 0.03 %w/w
US
FDA
Route: VAGINAL; Dosage form: CREAM; Potency: 0.35 %w/w
US
FDA
FDA NDC lists this ingredient in 55 active drug products and 65 total products.
US
FDA
openFDA substance registry classifies this ingredient as chemical.
US
FDA
openFDA substance registry classifies this ingredient as concept.